Arpida Files MAA for Intravenous Iclaprim
Posted on: Wednesday, 30 July 2008, 06:00 CDT
Arpida has submitted a marketing authorization application for intravenous iclaprim for the treatment of complicated skin and soft tissue infections to the European Medicines Agency.
The iclaprim marketing authorization application (MAA) contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (Assist-1 and Assist -2, in which approximately 1,000 patients were treated), the company said. Patients enrolled in the Phase III trials exhibited a high incidence of methicillin-resistant Staphylococcus aureus (MRSA) as causative pathogen.
In both of these two independent Phase III trials, intravenous iclaprim achieved the pre-specified primary endpoint of non-inferiority as compared to linezolid, according to the company. In the studies, iclaprim was well-tolerated with a safety profile which compared favorably with the comparator in the treatment of patients with complicated skin and soft tissue infections (cSSTIs).
In addition to the cSSTI indication, intravenous iclaprim is also being developed for the treatment of patients with hospital-acquired pneumonia, ventilator-associated pneumonia or healthcare-associated pneumonia suspected or confirmed to be due to Gram-positive pathogens.
Source: Datamonitor
Related Articles
- Glenmark Expects Launch of Crofelemer in ROW Countries(Developing Economies) by 2010 - Potential First-in-Class for HIV-Associated Diarrhea: Molecule Currently in Phase 3 Trials, Granted Fast Track Designation by US-FDA
- Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
- Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
- Novacea Initiates Phase 2 Trial of Asentar in Advanced Pancreatic Cancer
- Medivation Announces Treatment of First Patient in Phase 2 Trial of Dimebon(TM) in Huntington's Disease
- Depomed Initiates Dosing of Patients in Phase 2 Trial For Gabapentin GR For the Treatment of Menopausal Hot Flashes
- New Analyses From Phase 3 Trial in CLL Identify Relapsed Patients Who Maximally Benefit From Genasense(R) Treatment
- Exelixis Reports Additional Data From the Phase I Trial of XL999 in Patients With Advanced Solid Tumors
- GlycoGenesys, Inc. Achieves Primary Objective in Phase I Trial in Advanced Solid Tumors Preliminary Response Data on 14 Patients Shows 11 Achieve Stable Disease
 |
 |
User Comments (0)
RSS Feeds